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DEVELOPMENT OF COST CATALOGS FOR COST-EFFECTIVENESS 
ANALYSES IN GERMANY: RESULTS OF A FEASIBILITY STUDY
Scheuringer M, Krobot KJ
MSD Sharp & Dohme GmbH, Haar, Germany
OBJECTIVES: The aim of the review was to evaluate the efﬁcacy and safety of 
imiquimod 5% cream compared with vehicle for treating superﬁcial basal cell carci-
noma. METHODS: The analysis was performed in accordance with the rules of sys-
tematic review, based on the Cochrane Collaboration (Cochrane Reviewer’s 
Handbook) guidelines and the Health Technology Assessment Agency in Poland 
(AOTM) recommendations. RESULTS: Two multicenter, vehicle-controlled, random-
ized clinical trials of high quality were identiﬁed according to predeﬁned selection 
criteria. Treatment with imiquimod 5% cream once a day, 3 times per week resulted 
in signiﬁcantly greater complete response rate than vehicle in the period of 6 as well 
as 12 weeks. Probability of achieving the complete response rate (no histological evi-
dence of superﬁcial basal cell carcinoma in the excised post–treatment target tumor 
tissue) was signiﬁcantly greater for imiquimod 5% cream than vehicle and amounted 
to 18.2 (95% CI: 4.19; 84.84) and 146.14 (95% CI: 69.3; 323.75) respectively at 12 
and 6 weeks after treatment. The incidence of adverse events during the treatment 
period such as application site reaction including itching, pain and tenderness at the 
target tumor site and local skin reaction such as erythema, scabbing, were more fre-
quently recorded in the group of subjects who received imiquimod 5% cream in 
comparison with the vehicle group. CONCLUSIONS: Imiquimod 5% cream appears 
to be effective in the treatment of superﬁcial basal cell carcinoma. A 3 times a week 
dosing demonstrates high efﬁcacy results with acceptable safety proﬁle, during the 6 
as well as 12-week period.
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OBJECTIVES: The inclusion of indirect costs of illness in pharmacoeconomics studies 
is still a subject of considerable debate. The aim of the systematic literature review 
was to present the Polish economic practice concerning indirect costs evaluation of 
health care interventions. Study was conducted as a ﬁrst stage of a research project 
aimed at developing recommendation for methods of calculating indirect cost in 
Poland. METHODS: MEDLINE, EMBASE, Cochrane Library and Polish Medical 
Bibliography (PBL) were searched. Cut-off dates were set to February and March 
2009. The main speciﬁc keywords were ‘indirect costs’ or ‘costs and cost analysis’. 
Extracted data covered; type of study, disease under study, methods for evaluating 
indirect cost, measures of productivity loss value and share in total costs. RESULTS: 
Nineteen studies fulﬁlled the inclusion criteria for this review, of a total of 2300 refer-
ences. Seventeen out of 19 studies were cost of illness studies, 2 were economic analy-
ses. Methods of evaluating indirect costs were all based on human capital approach. 
The work absenteeism unit time measure used to value productivity loss were average 
salary (9/19), Gross Domestic Product (GDP) per capita (7/19), Gross National 
Product per capita (1/19), GDP per active worker (1/19), sold production of industry 
per active worker (1/19). Mean indirect costs amounted to 58% of total costs, with 
a range of 16%-98%. In 5 studies transfer payments (e.g. sick leave) were added to 
productivity loss category. CONCLUSIONS: Indirect cost is rarely included in the 
economic analyses in Poland. Different methods calculating indirect cost limit com-
parison between studies and call for development of robust and widely accepted 
methodology.
PMC14
THE COST OF ABSENTEEISM IN POLAND IN 2007—DIFFERENCES 
WITHIN THE PROVINCES
Macioch T, Jakubczyk M, Wrona W, Golicki D, Hermanowski T, Niewada M
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: Absenteeism is a major cause of indirect costs of illness. In Poland 
precise data regarding days of work lost due to illness are collected by Social Insurance 
Institution (ZUS). The aim of this study was to estimate absenteeism costs in Poland 
in 2007 based on average monthly gross wages and salaries. METHODS: Human 
capital approach was used to estimate absenteeism costs. We used ZUS and Central 
Statistical Ofﬁce (GUS) data. Average monthly gross wages and salaries estimates were 
calculated taking into consideration sex and province speciﬁc data. The analysis was 
based on an assumption that number of missed days includes only working days (252 
days per year). This assumption was tested within the range of 226 to 365 days (either 
including all calendar days or additionally subtracting 26 days of holidays). Values 
are presented in Euro (exchange rate: 1 Euro  4,50 PLN). RESULTS: Total costs of 
absenteeism in 2007 were estimated to amount of a5.3 billion (range a3.7–a5.9 
billion). In Silesia province the cost of day of sickness absence estimated per person 
employed was nearly twice as high as in Podlaskie province. Total costs of absenteeism 
calculated based on GDP per capita were similar, however there were some differences 
among territory speciﬁc estimations. Cost data based on GDP per capita or average 
monthly gross wages were approximately twice as high as ZUS data on the amount 
of funds spent on sick pay. CONCLUSIONS: Given that several predictors of sickness 
absence are not accounted to GDP per capita or average monthly gross wages and 
salaries based estimation, it seems that ZUS data on amount of mean sick pay may 
provide a reliable tool for absenteeism costs estimation in Poland.
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A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF 
CANCER CARE IN FRANCE
Baffert S1, Alfonsi A2, Florentin V2, Livartowski A1
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Economic evaluation requires identiﬁcation and measurement of resources from 
various viewpoints (patient, hospital, health insurance, society). Although the hospital 
resources are easily identiﬁed, resources such as travel expenses or loss of productivity 
are often more difﬁcult to measure or valorize. OBJECTIVES: To identify these 
various costs or cost determinants and specify for whom, for what and where they 
can be found in order to construct a standard costs toolkit including source data and 
costs per patient. METHODS: A check-list of costs items from various viewpoints has 
been established. Two approaches were combined: 1) The ﬁrst consisted of detailed       
examination of freely available databases, data derived from national institute or 
ministry websites, this ﬁrst step has been realized, and 2) The second consisted of 
analyzing costs or parameters usually difﬁcult to estimate. We tried to quantify these 
costs items. RESULTS: The various items and the various possible types of measure-
ments were listed. In the example of loss of productivity related to sick leave of a 
cancer patient, several parameters are required in order to perform the calculation by 
type of cancer. Gross domestic product is the starting point to determine the added 
value generated by an actively employed individual. We then calculated the mean 
added value of an actively employed individual (a3800 per month) and took the mean 
duration of sick leave of 120 days into account. Losses of productivity are estimated 
by cancer site and are about a1900 per incident patient and per year. According to 
national health insurance and survey on national thirty long-term diseases, travel 
expenses are about a500 on average per cancer patient and per year. CONCLUSIONS: 
Making a standard cost toolkit available could improve and foster the economic 
assessment processes in France.
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OBJECTIVES: Good quality health economic (HE) analysis could be an important 
tool in guiding (cost) efﬁciency in health care development in China. To review HE 
analyses from China and assessing their quality using a standardised questionnaire. 
METHODS: Search of MEDLINE and EMBASE (1964–2008) using key words:         
China, cost-utility analysis (CUA), cost-effectiveness analysis (CEA), cost-minimisation 
analysis (CMA), cost-beneﬁt analysis (CBA), and cost analysis (CA). Included were 
original HE evaluations examining a (medical) treatment/programme in a Chinese 
setting (including Hong Kong and Taiwan) describing costs and/or consequences in 
English or Chinese language. Quality was independently assessed by 4 raters using a 
13 items checklist derived from previously published HE assessments. Obtainable 
scores were 0 (“Incorrect”), 1 (“Not Reported”), 2 (“Doubtful”), 3 (“Acceptable”), 
4 (“Correct”) or N/A if not applicable. Post-hoc analyses were carried out to determine 
a time trend in quality or whether the observed differences in quality scores between 
languages existed. RESULTS: 36 articles were included for assessment: 17 CEAs, 7 
CBAs, 7 CUAs, and 5 CAs. No article used CMA. Majority of the evaluations was 
conducted in mainland China (64%), 31% in Hong Kong, and 5% in Taiwan. Mean 
quality score of all articles was ‘Acceptable’ (mean  3.1; SD  0.58) ranging from 
2.0–4.0. Post hoc analyses demonstrated that English publications had a signiﬁcant 
higher (; p  0.0005, Mann-Whitney U test) quality (mean  3.5; SD  0.45) compared 
to Chinese (mean  2.8; SD  0.46). No signiﬁcant time trend existed. CONCLU-
SIONS: HE analyses from China were considered ‘Acceptable’ and their quality was 
similar to previous assessments. Post-hoc analysis suggested a signiﬁcant difference 
between analyses published in English compared to Chinese. This study’s major limita-
tion is that low quality scores may be caused by poor reporting rather than poor 
research. Further research is needed to determine the underlying reasons of the quality 
and examine the impact of analyses on decision-making.
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OBJECTIVES: The indirect costs seem to be a relevant part of a total cost of illness, 
although there is no consensus whether they should be included in pharmacoeconomic 
analysis or which methods of calculations should be used. The aim of the survey was 
to collect data on practice and preferences of decision-makers and experts in health 
economics concerning the role and methods of calculating indirect costs in Poland. 
METHODS: The questionnaire contained 18 questions covering the need for indirect 
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costs calculation in economic evaluations, measures used to calculate indirect cost, 
and difﬁculties while performing indirect costs estimation. Questionnaires were 
handed out to participants of the 3rd International Symposium Evidence-Based Health 
Care in Cracow, mailed to the Polish Pharmacoeconomic Society members and dis-
tributed directly to experts. RESULTS: Fifty four pharmacoeconomists, health econo-
mists and decision-makers returned completed questionnaires. Mean age of respondents 
33,3 o 7,6 years; mean experience in health economics 4,7 o 5,2 years; 43%(23/54) 
of responders had non-economic background, 41%(22/54) reported government as a 
work environment. All (excluding one) responders indicated that indirect costs should 
be calculated in pharmacoeconomic studies (strongly agree 58%, agree 40%). Experts 
pointed out that indirect cost were calculated in only 24% of reports and represented 
on average 22% of total costs. Twenty three (i.e. 43%) responders indicated human 
capital approach as the best method to estimate cost from societal perspective; friction 
cost method came second best 11%(6/53); 42%(22/53) respondents had no opinion. 
The doers of economics evaluations pointed to GDP per capita (11/18), average salary 
(11/18), and costs of sick pay or injury beneﬁt (11/18) as measures which should be 
used to value production losses. CONCLUSIONS: Indirect costs are considered impor-
tant but seldom executed component of economic evaluations of health care interven-
tions in Poland. The lack of consensus and widely accepted methods for indirect cost 
evaluation support further research.
PMC18
ANALYSIS OF TRANSFERABILITY TOOLS FOR COST-EFFECTIVENESS 
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OBJECTIVES: Through the increase of economic evaluation studies in Korea, the 
question of transferability from different settings is becoming more and more impor-
tant. However, there are factors that may limit the transferability of study results 
such as variations in the epidemiology, relative pricing and the availability of health 
care resources. Already published by Welte, Boulenger and Urdahl, transferability 
tools are useful and easy to check the transferability among countries. This study 
assessed the transferability with these tools from other settings to Korea settings. 
METHODS: With three selected articles conducted in Belgium, Sweden and USA, 
we evaluated the transferability to Korean settings using 3 methodologies (Welte, 
Boulenger and Urdahl) and then identiﬁed those factors that can be appropriate 
to adapt in Korea settings. RESULTS: In case of Welte, Belgium and US study 
showed low correspondence for disease incidence like 0.4% vs. 0.01% in THR. And 
Sweden study showed different case-mix that the average age of TKR patients were 
higher than THR but Korea case was opposite. According to Boulenger method, the 
scores for Belgim, Sweden and US studies were 51.5, 75 and 75.6 separately. 
Low scores came from the discount and cost mainly due to insufﬁcient description. 
With Urdahl method, three studies well expressed for decision maker, but Belgium 
and Sweden studies did not describe the clinical research enough. The United 
States study explained in detail for the transition probabilities and modeling but the 
unit price and resource use were not related to Korea setting directly due to different 
pricing system. CONCLUSIONS: Through this evaluation, disease incidence, unit 
price and resource use showed low transferability in order to transfer to Korea. We 
could ﬁnd out that data and methods should be presented in a transparent way to 
improve transferability.
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EVALUATING AN ONLINE INCREMENTAL COST-EFFECTIVENESS 
CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT 
IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES
McGhan WF, Willey VJ, Peterson AM, Manke AA, Patel DD, Ajmera MR, Patel TB
University of the Sciences, Philadelphia, PA, USA
OBJECTIVES: To evaluate an online, freeware, incremental cost-effectiveness calcula-
tor that generates and plots results from a decision tree that utilizes Monte Carlo 
simulations for the variables related to the success probabilities, costs and utilities. 
METHODS: An online cost-effectiveness calculator and plotter were developed that 
incorporates a decision tree structure with Monte Carlo simulations to compare two 
interventions. This decision analysis calculator is available at www.healthstrategy.
com. This online tool uses JavaScript algorithms and was based on an MS Excel model 
description published by Hughes D. His spreadsheet can be downloaded from www.
liv.ac.uk/prg/model.xls. For this evaluation, the spreadsheet structure was modiﬁed 
slightly to match the more basic online tree. Log-normal and beta distributions are 
generated from variable inputs that can be modiﬁed in the web-based software that 
cover costs, utilities and probability of both success and failure for two treatment 
alternatives. RESULTS: The online calculator functions on most computer operating 
systems with JavaScript enabled browsers. The web-based tool creates a scatter plot 
of incremental costs versus incremental utilities in cost-effectiveness quadrants, and 
also graphs a cost-effectiveness acceptability curve. Although the min-max range of 
cost results were similar between the two tools, the range of utility results was greater 
with the web computations. The MS Excel spreadsheet model (1000 simulations) 
versus the online calculator (500 simulations) compared as follows: average incremen-
tal costs ($1919 vs. $1885), average incremental utilities:(0.058 vs. 0.054) and average 
incremental cost effectiveness ratio:($33,086 vs. $34,907). CONCLUSIONS: With 
this online decision tree and Monte Carlo simulator, the user can input their own 
distribution parameters, then generate and graph incremental costs, incremental utili-
ties and cost effectiveness acceptability curves. This web-based calculator has potential 
beneﬁt as a basic educational tool for students and health professionals interested in 
exploring these analytical approaches.
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IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF 
PRESCRIPTION DRUGS IN AUSTRIA
Heiderer B, Ortner T, Pfeffer N
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: Since 2005 Austrian regional sickness funds have been facing an 
increase in drug prescription costs of 7–8 % per year. In order to analyze these 
costs we developed a benchmarking system comparing drug prescription costs 
for 2007 of the regional sickness funds including two ratios split into a price and a 
volume component. Calculating the ratios at the high aggregate of the second 
ATC level revealed problems: The total savings potential seemed unrealistically high 
and could not be traced back to a speciﬁc ﬁeld of action. Therefore, the need for a 
re-design of the benchmarking system was more than necessary. METHODS: Since 
the cost-function is interpreted as a function of the distribution of prescriptions, price 
effects can be shown by adjusting the distribution. This is equivalent to shifting pre-
scriptions from speciﬁc drugs to others within a cluster. To legitimize this new method, 
the volume component of each sickness fund is normalized to the average level of 
prescriptions per beneﬁciary (ATC level 2), considering the fund’s distribution of pre-
scriptions in lower ATC levels. The process of clustering starts with substitutable drugs 
according to the national eco-list. After that these clusters are combined to groups at 
ﬁrst ATC level 5 and then ATC level 4. Within these groups the distributions of the 
funds are adjusted to the benchmark’s distribution. RESULTS: In each step of the 
clustering process we used various approaches, like the use of the eco-list or substitu-
tion of drugs by similar agents, to affect the price component. Moreover, the new 
method evaluates the prescription behaviour of contract physicians for each fund. 
CONCLUSIONS: The original method shows that a savings potential cannot be cal-
culated on an aggregate level. The new method provides a more detailed, step-by-step 
analysis and allows to identify—combined with medical quality assurance—possible 
ﬁelds of action.
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OBJECTIVES: Absenteeism costs estimated based on amount of mean sick pay (data 
provided by Social Insurance Institution—ZUS) were calculated for approximately 
a2.3 billion in 2007. The aim of this study was to evaluate the difference between 
absenteeism costs estimated either on mean sick pay or on gross value added in Poland 
in 2007. METHODS: Sickness absence data were derived by ZUS. Alternatively to 
ZUS data, absenteeism cost was estimated based on gross value added and structure 
of employed persons by sectors in sections of national economy derived by Central 
Statistical Ofﬁce (GUS). Based on ZUS and GUS data we calculated value of missed 
day per employed in speciﬁc sector of the economy. The analysis was based on an 
assumption that number of missed days includes only working days (252 days per 
year). Human capital approach was used to estimate the absenteeism costs. Values 
are presented in Euro (exchange rate: 1 Euro  4.50 PLN). RESULTS: Absenteeism 
costs were estimated to amount of a12 billion. Cost of missed days of work due to 
illness per person employed in mining and quarrying (a2062) was more than 5 times 
higher than cost per person employed in education (a380). Mean cost of absenteeism 
was estimated to amount of a1012 per employee. Mean cost of absenteeism estimated 
based on gross value added was more than 6 times higher than those estimated based 
on amount of funds spent on sick pay (a154 per employee). CONCLUSIONS: Given 
that ZUS data on amount of mean sick pay seem to provide reliable absenteeism costs 
in Poland, it would seemed that either data based on wages are underestimated or 
some compensative mechanisms exist in economy that limit indirect cost of sickness 
absence.
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Alcoholism is a chronic disease and the evaluation of its burden usually focuses on 
long-term co-morbidity and mortality. Clinical Trials evaluating new interventions for 
alcohol-dependent patients rarely last more than 12 to 24 months. OBJECTIVES: 
Develop a questionnaire capable of capturing principal resource use yet sensitive 
enough to show short-term economic beneﬁt of drugs developed to reduce consump-
tion in alcohol-dependent patients. METHODS: Comprehensive Medline literature 
search using keywords: Alcohol-related-disorders, economics, cost of illness. Further, 
experts panel discussions provided additional data. RESULTS: Two key cost drivers, 
hospitalisation and sick leaves were identiﬁed by the literature review. Expert ﬁndings 
related to costs of social consequences were incorporated. These three important 
resources were included in the questionnaire in addition to standard medical resource 
use consumption input. Finally, the following items were included: consultation visits, 
hospitalisations, sick leaves and working situation, living situation, social environ-
ment, accidents, arrests and domestic violence. The recall period is 3 months. DISCUS-
SION: A great deal of information is collected in this questionnaire in order to capture 
all relevant resources. Tests to validate the questionnaire in a real-life setting will be 
conducted (face validity, concurrent validity, and test-retest) in a cohort of dependent 
